

Pacgen Corporate Profile



CORPORATE OVERVIEW

Pacgen Biopharmaceuticals Corporation is a Canadian life sciences company focused on the development of therapeutics for the treatment of infectious and inflammatory diseases.

The Company recently reported positive results from its Phase IIb dose-ranging clinical trial for its lead product candidate, PAC-113, a novel anti-fungal drug. The Phase IIb clinical trial, which involved over 200 seropositive HIV patients, demonstrated that PAC-113 efficacy profile compares favorably to the efficacy of Nystatin, a current standard of care for topical treatment of oral Candidiasis.

Pacgen also has an earlier stage research program, PAC-G31P, which is currently being investigated in preclinical studies for its potential to treat neutrophilic inflammatory diseases.

The Company was founded in April 2004 and completed its IPO on the Toronto Venture Exchange in December 2006.

COMPANY HIGHLIGHTS & UPCOMING MILESTONES

- New plans for pipeline and building shareholder value, Q2/09
- Positive results for lead product candidate, PAC-113, from Phase IIb, Q2/08
- PAC-113, has a good safety profile from over 600 patients and low risk development pathway
 - Clear medical need in immunocompromised patients
 - Short clinical development timeline
 - Well-defined market opportunity
 - Phase II data package to attract partnering opportunity

PRODUCT PIPELINE	R&D	Preclinical	Phase I	Phase II	Phase III
PAC-113 Oral Candidiasis	██████████	██████████	██████████	██████████	
PAC-G31P ARDS, Asthma, COPD Pneumonia	██████████	██████████			
Early Stages PAC-525 & PAC-745	██████████				

MARKET FACTS

IPO: 12/2006
TSX-V: PGA

EXECUTIVE TEAM

Chung-Yu Wang, B.Sc., SIMP Diploma
Interim President & CEO

Christina Yip, BBA, CMA
CFO & Secretary

Fred Huang, BA, MBA
Sr. VP & COO

Lewis Choi, Ph.D.
VP, Research

BOARD OF DIRECTORS

Chung-Yu Wang, B.Sc., SIMP Diploma,
Co-founder & Chairman

Hassan Salari, Ph.D.
President & CSO,
Chemokine Therapeutics

Telvin Ju, Ph.D.
Sr. VP,
Maritime Transport Ltd.

Kevin McGarry, B.Sc., MBA *President,*
Lombard Life Sciences,
CEO,
Intelligent Hospital Systems

Alan Moore, Ph.D.
President & CEO,
Stem Cell Therapeutics.

LEAD PRODUCT

A Novel Anti-Fungal for Immunocompromised Patients

Opportunistic growth of *Candida* occurs in people with defective immune systems, and can be life-threatening if not treated. *Candida albicans* is the most common fungal pathogen among immunocompromised, hospitalized patients, accounting for roughly 50-60% of all bloodstream fungal isolates. Localized *Candida* infections, if untreated, can spread from the primary site of infection through the blood stream to cause a disseminated infection. Disseminated fungal infections are associated with a high mortality rate.

Current treatments for *Candida* infections are not effective in eliminating the infection or have serious side effects. PAC-113 has the potential to address this medical need.

PAC-113 is a 12 amino-acid antimicrobial peptide, derived from a naturally occurring histatin protein found in saliva, that has demonstrated a high level of in vitro activity against the fungus *Candida albicans*, including drug-resistant HIV patient isolates. Formulated as a mouthrinse, it can be swallowed, and to date has demonstrated potential to eliminate oral Candidiasis (infection of the mouth and esophagus).

Pacgen reported positive results from its Phase I/II trial on PAC-113 for the treatment of oral Candidiasis. The study was a head-to-head comparison between PAC-113 mouthrinse and Nystatin oral suspension. The trial established preliminary proof of efficacy for PAC-113 in eliminating clinical signs and symptoms of oral Candidiasis, as well as provided additional safety data.

The Company recently reported positive results from its Phase IIb dose-ranging study in patients with oral Candidiasis.

EARLY STAGE PROGRAMS

Pacgen also has an earlier stage research program, PAC-G31P, which is currently being investigated in preclinical studies for its potential to treat neutrophilic inflammatory diseases. Two other peptides, PAC-525 and PAC-725, are also being evaluated for their antibacterial and antiviral properties and potential respectively.

COMPANY ACHIEVEMENTS TO DATE

- Q2/08: Reported positive results from PAC-113 Phase IIb dose-ranging trial
- Q1/08: Completed C\$903K private placement financing
- Q2/07: Reported positive results from PAC-113 Phase I/II proof of concept clinical trial
- Q4/06: Completed IPO & raised ~ C\$7.1M
- Q4/06: Acquired pre-clinical drug candidate, PAC-G31P, through acquisition of IL Therapeutics Inc.
- Q105: In-licensed PAC-113 from Demegen Inc.
- Prior: Completed private financing ~C\$2.6M and incorporated Pacgen

MEDICAL AND SCIENTIFIC ADVISORY BOARD

Michael L. Barnett, D.D.S.
Clinical Professor of Periodontics/Endodontics, School of Dental Medicine, University at Buffalo (New York)

Mark FitzGerald, MB, MD, FRCP(I), FRCP(C), FACC
Director, Centre for Clinical Epidemiology & Evaluation, Vancouver Coastal Health research Institute; Head, UBC Respiratory Medicine Program; Head, Respiratory Medicine Division, Lung Centre, Vancouver General Hospital

John Gordon, Ph.D.
Prof. Dept. Veterinary Microbiology, University of Saskatchewan

William M. Nauseef, M.D.
Prof. Medicine and Microbiology, Director, Inflammation Program University of Iowa

Frank Oppenheim, DMD, Ph.D.
Prof. & Chairman, Dept. Periodontology & Oral Biology, School of Dental Medicine, Boston University; Associate Prof. Dept. Biochemistry, School of Medicine, Boston University

Neil Reiner, M.D.
Head, Divisions of Infectious Diseases, UBC & Vancouver Health & Hospital Sciences Centre

Brian Rowe, MD, MSc, CCFP (EM), FCCP,
Chair, Canada Research in Emergency Airway Diseases Research; Director, Dept. Emergency Medicine, Alberta University Hospital